Please assess the completion status of the following clinical trial:

Trial Title: Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian Countries

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patient suffers from recurrent MDD as the primary diagnosis according to DSM-IVTR™ criteria. The current Major Depressive Episode (MDE) should be confirmed using the Mini International Neuropsychiatric Interview (MINI)~* The patient has a MADRS total score ≥26~* The patient has a CGI-S score ≥4~* The reported duration of the current MDE is ≥3 months.~Other inclusion criteria may apply.~Exclusion Criteria:~- The patient meets any of the exclusion criteria listed in the protocol or, in the investigator's opinion, is unlikely to comply with the protocol or is unsuitable for any reason.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Vortioxetine (Lu AA21004) (Type: EXPERIMENTAL): None
- Venlafaxine extended release (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).